Merit E. Cudkowicz, Md
Clinical trials sponsored by Merit E. Cudkowicz, Md, explained in plain language.
-
New drug DNL343 tested in major ALS trial – hope for slowing disease?
Disease control CompletedThis study tested a drug called DNL343 in 249 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if DNL343 could slow the disease and help people live longer. The trial used a flexible platform design to test multiple treatments at once.
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could this daily pill slow ALS?
Disease control CompletedThis completed Phase 2/3 trial tested an oral drug called ABBV-CLS-7262 in 310 people with ALS. Participants took the drug or a placebo once daily for 24 weeks. The study measured how fast the disease progressed and survival rates. The goal was to see if the drug could slow ALS a…
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC